Prevalence of cognitive impairment (CI) in patients with multiple sclerosis (MS): A systematic review and meta-analysis

Abstract

BACKGROUND: One of the complications of multiple sclerosis (MS) is cognitive impairment (CI). The prevalence of CI is reported variously in previous studies. The goal of this systematic review and meta-analysis to estimate pooled prevalence of CI in patients with MS and also the prevalence of CI based on the type of applied test. METHODS: Two independent researchers systematically searched PubMed, Scopus, EMBASE, Web of Science, and google scholar as well as gray literature (conference abstracts, references of the references) which were published before up January 2022. RESULTS: We found 4089 articles by literature search, after deleting duplicates 3174 remained. Ninety articles remained for meta-analysis. The pooled prevalence of CI using all types of tests was 41 (95 CI: 38-44) (I2=91.7, p<0.001). The pooled prevalence of CI using BRB test was 39 (95CI: 36-42) (I2=89, p<0.001). The pooled prevalence of CI using BICAMS was 44 (95CI: 37-51, I2=95.4, p<0.001). The pooled prevalence of CI using MACFIMS was 44 (95 CI: 36-53) (I2=89.3, p<0.001). CONCLUSIONS: The pooled prevalence of cognitive impairment in patients with MS is estimated as 41, so CI it should be considered by clinicians.